Philips Respironics announced last Monday that it’s stopping sales of their breathing machines within the U.S. following a mid-2021 product recall. The decision, as reported by The New York Times, was settled with the FDA over reports of continuing issues with the company’s ventilators and CPAP devices, or continuous positive airway pressure machines. Philips, the Dutch manufacturing giant, is working under a tentative agreement that would cost the company almost $400 million — but company executives have reportedly “set aside $393 million for operational changes and upgrades needed to comply,” per The Associated Press.
CPAP (Continuous Positive Airway Pressure) therapy is an effective non-invasive treatment for obstructive sleep apnea. Let's dispel the myths surrounding this device which doctors say can become your good friend. TheHealthSite.com